search
Back to results

Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease (LOPD01)

Primary Purpose

Glycogen Storage Disease Type II, Pompe Disease (Late-onset)

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Inspiratory Muscle Training (IMT)
Inspiratory Muscle Training (IMT) + Air Stacking
Sponsored by
Fondazione Don Carlo Gnocchi Onlus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glycogen Storage Disease Type II focused on measuring Pompe Disease (Late-onset) (LOPD), Neuromuscular Disease (NMD), Inspiratory Muscle Training (IMT)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Late On-set Pompe Disease diagnosis already in Enzyme Replacement Therapy (ERT) since 12 months Forced Vital Capacity <80% predicted or Forced Vital Capacity >80% but with Postural Drop >25-30% Exclusion Criteria: Severe Cardiologic or Respiratory comorbidities Complete dependence on ventilation

Sites / Locations

  • IRCCS S. Maria Nascente - Fondazione Don Carlo GnocchiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Inspiratory Muscle Training (IMT)

Inspiratory Muscle Training (IMT) + Air Stacking

Arm Description

Use of Powerbreathe Device associated with aerobic excercise tailored for walking and non-walking subjects

Use of Powerbreathe Device and application of Air-Stacking maneuvres associated with aerobic excercise tailored for walking and non-walking subjects

Outcomes

Primary Outcome Measures

Changes in Vital Capacity (VC) through different time-points
Quantity of air moved inside and outside the respiratory system.
Variations in Postural Drop (PD) measured through different time-points
Non supine Forced Vital Capacity (FVC)% - supine Forced Vital Capacity (FVC)%
Changes in Maximal Inspiratory Pressure (MIP) measured through different time-points
Maximal negative inspiratory pressure created by the patient through 5 seconds, measured in cmH2O.

Secondary Outcome Measures

Variations of the fitness level (6-MWT)
Change in aerobic excercise tolerance
Variations of the fitness level (6-PBRT)
Change in aerobic excercise tolerance
Changes in Quality of life (Maugeri-Respiratory-Failure 28)
individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)
Changes in Quality of life (Short Form-36)
Individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)
Changes in Quality of life (Individualized-Neuromuscular-Quality-of-Life)
individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)

Full Information

First Posted
February 16, 2023
Last Updated
July 11, 2023
Sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
Associazione Italiana Glicogenosi (AIG), Associazione Riabilitatori Insufficienza Respiratoria (ArIR), U.O.C. AO Ospedali Riuniti Villa Sofia-Cervello, Palermo, S.C. di Pneumologia Azienda Sanitaria Universitaria Integrata di Trieste
search

1. Study Identification

Unique Protocol Identification Number
NCT05951790
Brief Title
Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease
Acronym
LOPD01
Official Title
Efficacy and Feasibility of Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease: a Multicentre, Cross-over Randomized Control Trial (RCT)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2023 (Actual)
Primary Completion Date
June 1, 2023 (Actual)
Study Completion Date
April 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
Associazione Italiana Glicogenosi (AIG), Associazione Riabilitatori Insufficienza Respiratoria (ArIR), U.O.C. AO Ospedali Riuniti Villa Sofia-Cervello, Palermo, S.C. di Pneumologia Azienda Sanitaria Universitaria Integrata di Trieste

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this multicentre, randomized and controlled cross-over trial is to evaluate the efficacy of a programme of Inspiratory Muscle Training in subjects with Late On-set Pompe Disease (LOPD). The main question is to: verify changes in Forced Vital Capacity, Postural Drop, Maximal Inspiratory Pressure, Maximal Expiratory Pressure, Peak expiratory cough pressure, Maximal Inspiratory Capacity, six- minute walk test and or 6-minute pegboard ring test.- measure changes in some questionnaries investigating dispnoea and quality of life (Short-Form 36, Individualized-Neuromuscular-Quality-of-Life, Maugeri-Respiratory-Failure 28, Borg scale, Dispnoea 12, Mulditimensional Dispnea Profile, modified Medical Research Council, Fatigue Severity Scale, Epsworth Scale, Visual Analogue Scale). Measurement will take place at baseline and after one, three, four, six and twelve months. Participants will undergo a specific treatment consisting of aerobic exercise and Inspiratory Muscle Training with Powerbreathe device or Air-Stacking. Researchers will study if Powerbreathe device is more effective than Air-stacking maneuvres
Detailed Description
This is an experimental study (Multicentre, randomized and controlled cross-over trial) with low risk impact. The literature supports us in determining that the risks of respiratory muscle fatigue, which will be carefully evaluated through standardized measures of dyspnea, are nonexistent1Patients will undergo respiratory function tests with evaluation of the following parameters: forced vital capacity (FVC %) sitting on their back with measurement of postural fall ie the percentage difference between FVC in sitting and supine position (%PD), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), peak expiratory flow during coughing (PCEF), maximum insufflation capacity (MIC), 6-minute walk test (6MWT) for walking patients and six-minute pegboard and ring test (6PBRT) "Ring testing" for non-dombulants. Also participants will compile some questionnaries investigating dispnea, sleep and quality of life (Short Form-36, Individualized-Neuromuscular-Quality-of-Life, Maugeri-Respiratory-Failure 28, Borg scale, Dispnea-12, Muldimensional Dispnea Profile, modifier Medical Research Council, Fatigue Severity Scale, Epsworth Sleepness Scale and Visual Analogue Scale). The evaluation phase identifies zero time (T0). Subsequently, patients enrolled will be randomized to the first treatment (training of inspiratory muscles) or the second treatment (training of inspiratory muscles + air-stacking). Each training period of the respiratory muscles will last 2 months and will be followed by a wash out period of 1 month before moving on to the next arm treatment. The first month patients will perform only aerobic activity. The total treatment time will be 6 months. walking patients will perform an aerobic activity of their choice, according to individual preferences, involving as many muscles as possible (e.g. walking, pedaling, climbing stairs) for at least 30 minutes 3 v/week of sufficient intensity to determine an increase in heart rate (FC) 60% of the predicted FC max or a perception of effort between 4-6 of the modified Borg scale. For patients who are not walking, there are activities with arms not supported (initially without load and then with small weights of ½ Kg, 1 Kg, 2 Kg) involving the main muscle groups of the upper limbs performed for at least 30 minutes 3 v/week and of such intensity as to generate a perception of effort between 4-6 of the modified Borg scale. The type of instrument used for the training of inspiratory muscles will be the Powerbreathe KHP2 which is a tool with variable load (Fig 1) and can be set according to the characteristics of individual patients as explained below. Intensity and mode of training of inspiratory muscles (8-10 repetitions for 4 sets/day with breaks of at least 2 minutes between one series and the other for 6 days/week) Initial load 30% MIP (the load must be progressively increased to the maximum tolerated level) Patients will be instructed to perform a complete inhalation and exhalation at each respiratory act (about 70% of their CVF). The respiratory effort perceived by patients should ideally be between 4-6 of the modified Borg scale. Increase of 2 cmH2O with Borg < 4 or average inhaled volume < 70% of CVF. Air "stacking" maneuver in the respiratory shaft through the use of an Ambu balloon: the patient encases and retains a series of volumes of air until reaching his MIC (Maximum Inspiratory Capacity) for 10 maneuvers/ day for 6 days/ week. Patients will be evaluated at the reference hospital centre and will perform the programme at home. They will be followed by physiotherapists specialized in respiratory physiotherapy and the intervention will be articulated with home visits alternated with reinforcement calls and monitoring in equivalent number in the two treatment groups. Follow-up measures will be performed at 1 month (T1), 3 months (T3), 4 months (T4), 6 months (T6) and 12 months (T12). Patient diaries and records of functional data and load increases will be evaluated. A subject who performs at least 2/3 sessions per week of aerobic training for at least 5/6 months will be defined as adhering to the treatment; 5/6 sessions per week of training of breathing muscles with at least 3/4 series completed, 5/6 sessions per week of air stacking with 8/10 managements carried out. Also will be measured: Number of phone calls/video calls made by patients in addition to those scheduled; Number of patients in drop out; Number of accesses to the prescribing center for any clinical urgencies; Number of unscheduled visits; Questionnaire of satisfaction to the use of the device. Randomization will be carried out through a derived Internet randomization software in order to ensure the concealment of assignments. Twenty participants will be randomized (1:1) in blocks of 2 to the trial treatment or control arm. The randomization model will be defined by the study statistician. Based on the defined parameters, the module creates an assignment table model, which is used to structure the randomization table. The module also monitors the overall progress of the assignment and the allocation of randomized participants. The doctor, to collect the data, will use as a password protected Microsoft Excel database. This will happen after the pre-test evaluation and before the first treatment session. The randomization field will always be locked and unmodifiable both before and after the randomization of a participant. The randomization documentation will be stored electronically in Excel and will include the participant identifier, the assignment to the treatment or control arm and the date and time of randomization. This electronic register of randomization will be accessible only to the doctor (not blind). Within each study arm, categorical data will be presented as frequencies and percentages; continuous data will be presented as mean, median, standard deviation and range. Primary analysis of the study will be conducted on intention-to-treat (ITT) cases. Non-directional hypotheses (two-tailed tests) will be tested. The measurement of the primary outcome defined by changes in vital capacity, drop posture and maximum inspiratory pressure will be evaluated with alpha=0.05. The results of the secondary outcomes will be evaluated with and without adjustment for multiple comparisons using the Bonferroni test. In addition, the analyses will be conducted on the participants who completed the study. All data analysis will be performed with the statistical software Jamovi version 2.3.3. No intermediate analysis.It is expected from this study that the training of inspiratory muscles can contribute to an improvement in respiratory function and that this results in a better quality of life

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glycogen Storage Disease Type II, Pompe Disease (Late-onset)
Keywords
Pompe Disease (Late-onset) (LOPD), Neuromuscular Disease (NMD), Inspiratory Muscle Training (IMT)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Inspiratory Muscle Training (IMT)
Arm Type
Active Comparator
Arm Description
Use of Powerbreathe Device associated with aerobic excercise tailored for walking and non-walking subjects
Arm Title
Inspiratory Muscle Training (IMT) + Air Stacking
Arm Type
Experimental
Arm Description
Use of Powerbreathe Device and application of Air-Stacking maneuvres associated with aerobic excercise tailored for walking and non-walking subjects
Intervention Type
Device
Intervention Name(s)
Inspiratory Muscle Training (IMT)
Intervention Description
Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
Intervention Type
Device
Intervention Name(s)
Inspiratory Muscle Training (IMT) + Air Stacking
Intervention Description
Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
Primary Outcome Measure Information:
Title
Changes in Vital Capacity (VC) through different time-points
Description
Quantity of air moved inside and outside the respiratory system.
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Variations in Postural Drop (PD) measured through different time-points
Description
Non supine Forced Vital Capacity (FVC)% - supine Forced Vital Capacity (FVC)%
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Changes in Maximal Inspiratory Pressure (MIP) measured through different time-points
Description
Maximal negative inspiratory pressure created by the patient through 5 seconds, measured in cmH2O.
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Secondary Outcome Measure Information:
Title
Variations of the fitness level (6-MWT)
Description
Change in aerobic excercise tolerance
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Variations of the fitness level (6-PBRT)
Description
Change in aerobic excercise tolerance
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Changes in Quality of life (Maugeri-Respiratory-Failure 28)
Description
individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Changes in Quality of life (Short Form-36)
Description
Individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month
Title
Changes in Quality of life (Individualized-Neuromuscular-Quality-of-Life)
Description
individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (WHO)
Time Frame
From Baseline to first month, third, forfth, sixth and twelth month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Late On-set Pompe Disease diagnosis already in Enzyme Replacement Therapy (ERT) since 12 months Forced Vital Capacity <80% predicted or Forced Vital Capacity >80% but with Postural Drop >25-30% Exclusion Criteria: Severe Cardiologic or Respiratory comorbidities Complete dependence on ventilation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elena Compalati, RT
Phone
3209727740
Ext
+39
Email
ecompalati@dongnocchi.it
First Name & Middle Initial & Last Name or Official Title & Degree
Marta Lazzeri, RT
Email
marta.lazzeri@ospedaleniguarda.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paolo Banfi, MD
Organizational Affiliation
IRCCS Fondazione Don Carlo Gnocchi
Official's Role
Principal Investigator
Facility Information:
Facility Name
IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi
City
Milan
ZIP/Postal Code
20146
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paolo Banfi, MD
Phone
+390240308812
Email
pabanfi@dongnocchi.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23587901
Citation
Ambrosino N, Confalonieri M, Crescimanno G, Vianello A, Vitacca M. The role of respiratory management of Pompe disease. Respir Med. 2013 Aug;107(8):1124-32. doi: 10.1016/j.rmed.2013.03.004. Epub 2013 Apr 12.
Results Reference
result
PubMed Identifier
30944902
Citation
Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, Mongini TEG, Sansone VA, Toscano A, Siciliano G. The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence. Acta Myol. 2018 Dec 1;37(4):241-251. eCollection 2018 Dec.
Results Reference
result
PubMed Identifier
33711277
Citation
Pellegrino GM, Corbo M, Di Marco F, Pompilio P, Dellaca R, Banfi P, Pellegrino R, Sferrazza Papa GF. Effects of Air Stacking on Dyspnea and Lung Function in Neuromuscular Diseases. Arch Phys Med Rehabil. 2021 Aug;102(8):1562-1567. doi: 10.1016/j.apmr.2021.01.092. Epub 2021 Mar 9.
Results Reference
result
PubMed Identifier
28649546
Citation
Jevnikar M, Kodric M, Cantarutti F, Cifaldi R, Longo C, Della Porta R, Bembi B, Confalonieri M. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease. Mol Genet Metab Rep. 2015 Oct 29;5:67-71. doi: 10.1016/j.ymgmr.2015.09.007. eCollection 2015 Dec.
Results Reference
result
PubMed Identifier
26381077
Citation
Jones HN, Crisp KD, Robey RR, Case LE, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining. Mol Genet Metab. 2016 Feb;117(2):120-8. doi: 10.1016/j.ymgme.2015.09.003. Epub 2015 Sep 8.
Results Reference
result
PubMed Identifier
27106274
Citation
Aslan GK, Huseyinsinoglu BE, Oflazer P, Gurses N, Kiyan E. Inspiratory Muscle Training in Late-Onset Pompe Disease: The Effects on Pulmonary Function Tests, Quality of Life, and Sleep Quality. Lung. 2016 Aug;194(4):555-61. doi: 10.1007/s00408-016-9881-4. Epub 2016 Apr 22.
Results Reference
result
PubMed Identifier
30430231
Citation
Wenninger S, Greckl E, Babacic H, Stahl K, Schoser B. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study. J Neurol. 2019 Jan;266(1):133-147. doi: 10.1007/s00415-018-9112-4. Epub 2018 Nov 14.
Results Reference
result
PubMed Identifier
31303277
Citation
Jones HN, Kuchibhatla M, Crisp KD, Hobson Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): A protocol for a sham-controlled clinical trial. Mol Genet Metab. 2019 Aug;127(4):346-354. doi: 10.1016/j.ymgme.2019.05.001. Epub 2019 May 8.
Results Reference
result
PubMed Identifier
33127291
Citation
Jones HN, Kuchibhatla M, Crisp KD, Hobson-Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, Kishnani PS. Respiratory muscle training in late-onset Pompe disease: Results of a sham-controlled clinical trial. Neuromuscul Disord. 2020 Nov;30(11):904-914. doi: 10.1016/j.nmd.2020.09.023. Epub 2020 Sep 28.
Results Reference
result
PubMed Identifier
34522820
Citation
Human A, Morrow BM. Inspiratory muscle training in children and adolescents living with neuromuscular diseases: A pre-experimental study. S Afr J Physiother. 2021 Aug 31;77(1):1577. doi: 10.4102/sajp.v77i1.1577. eCollection 2021.
Results Reference
result
PubMed Identifier
33881155
Citation
Pick HJ, Faghy MA, Creswell G, Ashton D, Bolton CE, McKeever T, Lim WS, Bewick T. The feasibility and tolerability of using inspiratory muscle training with adults discharged from the hospital with community-acquired pneumonia. Adv Respir Med. 2021;89(2):216-220. doi: 10.5603/ARM.a2021.0002. Epub 2021 Apr 21.
Results Reference
result
PubMed Identifier
7480122
Citation
McCool FD, Tzelepis GE. Inspiratory muscle training in the patient with neuromuscular disease. Phys Ther. 1995 Nov;75(11):1006-14. doi: 10.1093/ptj/75.11.1006.
Results Reference
result

Learn more about this trial

Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease

We'll reach out to this number within 24 hrs